Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions
B-cell Malignancies
Interventions
DRUG

Tirabrutinib

Capsules or tablets administered orally

DRUG

Idelalisib

Tablets administered orally twice daily

DRUG

Entospletinib

Tablets administered orally

DRUG

Obinutuzumab

Administered intravenously

Trial Locations (15)

3110

Institut Universitaire du Cancer-Oncopole I.U.C.T-O, Toulouse

20007

Georgetown University Medical Center, Washington D.C.

33604

Chu Haut Leveque, Pessac

34295

Hopital Saint Eloi, Montpellier

46506

Indiana University Health Goshen Center for Cancer Care, Goshen

59037

CHRU de Lille, Hopital Claude Huriez, Lille

69310

Centre Hospitalier de Lyon Sud, Pierre-Bénite

97239

Oregon Health and Science University, Portland

CB20QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

CF14 4XW

Cardiff and Vale Health Board, Clinical Research Facility, Cardiff

LS9 7TF

Leeds Teaching Hosptials NHS Trust, Dept of Haematology, Leeds

LE1 5WW

University Hospitals of Leicester NHS Trust, Leicester

M20 4BX

The Christie NHS Foundation Trust, Manchester

PL68DH

Plymouth Hospitals NHS Trust, Plymouth

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY